Effects of a supersulfated low molecular weight heparin (IK-SSH) on different hemostatic parameters

Haemostasis

Volumn 28, Issue 1, 1998, Pages 45-56

  Glusa, E ^a   Barthel, W ^b   Schenk, J ^c   Radziwon, P ^c   Butti, A ^d   Markwardt, F ^c   Breddin, K H ^c,e  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b HELIOS KLINIKUM ERFURT   (Germany)

^c International Institute of Thrombosis and Vascular Diseases   (Germany)

^d Keton Farmaceutici   (Italy)

^e NONE   (Germany)

Author keywords

Activated partial thromboplastin time; Low molecular weight heparin; Thrombin generation; Tissue factor pathway inhibitor

Indexed keywords

HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SULFATION; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME;

EID: 0032447644     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022383     Document Type: Article

References (39)

1. Verstraete M: Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990;40:498-530.
2. Hirsh J, Levine MN: Low molecular weight heparin. Blood 1992;79:1-17.
3. Leizorovicz A, Simonneau G, Decousus H, Boissel J: Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis. Br Med J 1994;309:299-304.
4. Breddin HK: Low molecular weight heparins and bleeding. Semin Thromb Hemost 1989;15:401-404.
5. Bergqvist D: Perioperative hemorrhagic complications in patients on low molecular weight heparins. Semin Thromb Hemost 1993;19(suppl 1):128-130.
6. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
7. Harenberg J, Maisch R, Heene DL: Tissue factor pathway inhibitor: Proposed heparin recognition region. Blood Coagul Fibrinolysis 1995;6(suppl 1):S50-S56.
8. Hoppensteadt DA, Jeske W, Fareed J, Bermes EW: The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low molecular weight heparin. Blood Coagul Fibrinolysis 1995;6(suppl 1):S57-S64.
9. Fareed J, Jeske W, Hoppensteadt D, Clariziop R, Walenga JM: Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 1996;22(suppl 1):77-91.
10. Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U: Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemost 1982;47-244-248.
11. Ockelford PA, Carter CJ, Mitchell L, Hirsh J: Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982;28:401-409.
12. Ofosu FA, Fernandez F, Anvari N, Caranobe C, Dol F, Cadroy Y, Petitou M, Mardiguian J, Sie P, Boneu B: Further studies on the mechanisms for the antithrombotic effects of sulfated polysaccharides in rabbits. Thromb Haemost 1988;60:188-192.
13. Walenga J, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J: Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987;46:187-198.
14. Walenga J, Bara L, Petitou M, Samama M, Fareed J, Choay J: The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb Res 1988;51:23-33.
15. Naggi A, Torri G, Casu B, Pangrazzi J, Abbadini M, Zametta M, Donati MB, Lansen J, Maffrand JP: Supersulfated heparin fragments, a new type of low molecular weight heparin. Physiochemical and pharmacological properties. Biochem Pharmacol 1987;36:1895-1900.
16. Fareed J, Walenga JM, Hoppensteadt D, Huan X, Racanelli A: Comparative study on the in vitro and in vivo activities of seven low molecular weight heparins. Hemostasis 1988;18(suppl 3):3-15.
17. Fareed J, Walenga J, Kumar A, Rock A: A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemost 1985;11:155-175.
18. Weichert W, Breddin HK: Effect of low molecular weight heparins on laser induced thrombus formation in rat mesenteric vessels. Haemostasis 1988;18(suppl 3):55-63.
19. Krupinski K, Breddin HK, Casu B: Anticoagulant and antithrombotic effects of chemically modified heparins and pentosanpolysulfate. Haemostasis 1990;20:81-92.
20. Fischer R, Kaiser B, Glusa E: Experimental studies on the antithrombotic effectiveness of a supersulfated low molecular weight heparin (SSH 14) in rats. Ann Hematol 1996;72(suppl 1):A73.
21. Basic-Micic M, Roman C, Herpel U, Kling E, Scholz B, Breddin HK: Platelet-induced thrombin generation time: A new sensitive global assay for platelet function and coagulation. Haemostasis 1992;22:309-321.
22. Breddin K: Zur Messung der Thrombozytenadhäsivität. Thromb Diath Haemorrh 1964;12:269-280.
23. Mielke CH: Aspirin prolongation of the template bleeding time: Influence of venostasis and direction of incision. Blood 1982;60:1139-1142.
24. Fareed J, Hoppensteadt DA, Walenga JM: Current perspectives on low molecular weight heparins. Semin Thromb Hemost 1993;19(suppl 1):
25. Hoppensteadt DA, Jeske W, Ahsan A, Walenga JM, Fareed J: Biochemical and pharmacological profile of defined molecular weight fractions of heparin. Semin Thromb Hemost 1993;19(suppl 1):12-19.
26. Hoppensteadt DA, Haas S, Breddin HK, Fareed J: Modulation of laboratory parameters after therapeutic and prophylactic administration of Sandoparin. Semin Thromb Hemost 1993;19(suppl 1):31-35.
27. Bacher P, Horst B, Breyer HG, Hoppensteadt DA, Walenga JM, Fareed J: Postoperative monitoring of low molecular weight heparin prophylaxis in high risk patients. Semin Thromb Hemost 1993;19(suppl 1):73-78.
28. Harenberg J, Haaf B, Schäfer M, Dempfle CE, Stehle G, Heene DL: Antifactor Xa determination in blood: A new method for controlling heparin therapy. Semin Thromb Hemost 1993;19(suppl 1):79-85.
29. Maffrand JP, Herbert JM, Bernat A, Defreyn G, Delebasse D, Savi P, Pinot JJ, Sampol J: Experimental and clinical pharmacology of pentosan polysulfate. Semin Thromb Hemost 1991;17(suppl 2):186-198.
30. Haas S, Stemberger AW, Fritsche HM, Wendt P, Blümel G: Study of the glycosaminoglycan polysulfate on various parameters of blood coagulation. Semin Thromb Hemost 1991;17(suppl 2):214-218.
31. Fareed J, Coker S, Iqbal O, Hoppensteadt D, Walenga JM: Pharmacodynamics of a sulfated lactobionic acid amide-derived antithrombotic agent (Aprosulate) in primates. Semin Thromb Hemost 1991;17(suppl 2):147-152.
32. Basic-Micic M, Breddin K: Effects of unfractionated and low molecular weight heparin on platelet-induced thrombin formation time and platelet adhesion. Semin Thromb Hemost 1993;19(suppl 1):22-28.
33. Sandset PM, Abildgaard U, Larsen ML: Heparin induces release of extrinsic pathway inhibitor (EPI). Thromb Res 1988;50:803-813.
34. Enjyoji K, Myata T, Kato H, Kamikubo Y: Identification of Kunitz domain 3 of tissue factor pathway inhibitor (TFPI) as second binding site for the optimal inhibition of factor Xa (abstract). Thromb Haemost 1993;69:680.
35. Bendetowicz AV, Pacaud E, Beguin S, Uzan A, Hemker HC: On the relationship between molecular mass and anticoagulant activity of a low molecular weight heparin (enoxaparin). Thromb Haemost 1992;67:556-562.
36. Valentin S, Ostergaard P, Nilsen JL, Nordfang O: Comparison of different glycosaminoglycans with respect to their capacity for binding of tissue factor pathway inhibitor (abstract). Thromb Haemost 1993;69:682.
37. Wun T: Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood 1992;79:430-438.
38. Boczkowska-Radziwon B, Radziwon P, Schenk J, Butti A, Breddin HK: Die antikoagulatorische Wirkung von supersulfatiertem, niedermolekularem Heparin (SSH) ist durch TFPI-Freisetzung vermittelt; in Heinle H, Schulte H, Breddin HK (eds): Endothelfunktion und Arteriosklerose. Stuttgart, Kohlhammer, 1994, pp 184-188.
39. Kaiser B, Glusa E, Hoppensteadt DA, Fareed J, Breddin HK, Amiral J: Increase in TFPI levels after administration of a supersulfated low-molecular weight heparin (IK-SSH) into humans. Blood Coagul Fibrinolysis, in press.